LEXICON PHARMACEUTICALS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-06-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-06-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $0.00.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $0.00.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $15.71M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-11-06 | |
| 2022-12-31 | $0.00 10-K · filed 2023-03-03 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-03 | |
| 2020-12-31 | $15.71M 10-K · filed 2023-03-03 | |
| 2019-12-31 | $0.00 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |